North Bay Educational Symposium CANP North Bay Chapter January 30, 2016 Gregg Hopkins, MD, FACC Sutter Medical Group of the Redwoods.

Slides:



Advertisements
Similar presentations
Summary Prepared by Melvyn Rubenfire, MD
Advertisements

Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Lipid Disorders and Management in Diabetes
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
2013 ACA/AHA Blood Cholesterol Guidelines University of Southern California – Los Angeles County Hospital Journal Club Thursday, January 23 rd, 2014 José.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
An Academic Research Organization of Brigham and Women’s Hospital and Harvard Medical School LAPLACE-TIMI 57 Primary Results A Double-blind, Randomized,
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Global impact of ischemic heart disease World Heart Federation, 2011.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
Praluent® - alirocumab
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2013 ACC/AHA Guideline on the Treatment of Blood.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
J Am Coll Cardiol. 2015;65(24): doi: /j.jacc Figure Legend:
R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.
Neal S. Perlmutter, MD, FACC Overlake Medical Clinics Cardiology
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Title slide.
Safi U. Khan MD; John Pamula MD
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
2013 ACC/AHA Guideline on Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
Cholesterol practice questions
The Anglo Scandinavian Cardiac Outcomes Trial
Senior Medical Director, Cardiovascular
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
The Latest Lipid Guidelines:
FATS- Familial Atherosclerosis Treatment Study
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
PCSK9 Inhibitors Post-CVOTs
Neil J. Stone et al. JACC 2014;63:
Drug induced myopathy Edition
Patients aged 85yrs and over
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
What's New in Dyslipidemia?
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Contemporary Evidence-Based Guidelines
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
LRC-CPPT and MRFIT Content Points:
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
An Update on PCSK9 Inhibitors
Goals & Guidelines A summary of international guidelines for CHD
Train-the-Trainer Cases
Pandemic Lipid Edition
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Train-the-Trainer Cases
Train-the-Trainer Cases
Putting Your Skills to the Test
PCSK9 Inhibitors and Real-World Evidence
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Section 6: Update on lipid treatment guidelines
Presentation transcript:

North Bay Educational Symposium CANP North Bay Chapter January 30, 2016 Gregg Hopkins, MD, FACC Sutter Medical Group of the Redwoods

2013 ACC/AHA Guidelines on Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

What has Changed Compared to ATP-III Guidelines (2001)? Initiate either moderate-intensity or high-intensity statin therapy for patients who fall into the four treatment categories Unlike ATP-III, do not titrate to a specific LDL cholesterol target Measure lipids during follow-up to assess adherence to treatment, not to achieve a specific LDL target

Intensity of Statin Therapy in Primary and Secondary Prevention

Recommended LDL goal is <100 mg/dL – An LDL goal of <70 mg/dL is a therapeutic option on the basis of available clinical trial evidence, especially for patients at very high risk Grundy, S. et al., Circulation 2004;110: High-Risk Persons Recommendations for Modifications to Footnote the ATP III Treatment Algorithm for LDL Levels

Four Major Statin Benefit Groups 1)Clinical ASCVD 2)LDL >190 3)Diabetics, y/o, with LDL but no clinical ASCVD 4)10-year ASCVD risk >7.5% without clinical ASCVD or diabetes

Definition of Clinical ASCVD Clinical ASCVD is defined by the inclusion criteria of secondary prevention statin RCTs: –acute coronary syndromes –history of MI –stable or unstable angina –coronary or other arterial revascularization –stroke or TIA –peripheral arterial disease

“Don’t Give More Patients Statins” -- Rita Redberg’s Opinion in NYTimes Lowering ASCVD risk threshold from 10% to 7.5% increases number of “healthy people” treated with statins by 70%. NNT of 140 in primary prevention, with 18% experiencing side effects Skeptical that Big Pharma has influenced guideline recommendations

2010 ACC/AHA Guidelines on Screening for CAD CAC scoring is reasonable (level of evidence B) in asymptomatic adults with intermediate Framingham risk (10-20% chance of CV event in 10 yrs) CAC scoring “may be reasonable” in those at low-intermediate risk (6-10% chance of CV event in 10 yrs)

CAC Scoring to Predict Coronary Events in Asymptomatic Patients Most coronary events occur from rupture of “vulnerable” plaque, not fixed lesions Unstable plaque tends to co-localize with areas of coronary calcification Patients with high CAC scores have a high likelihood of vulnerable plaque rupture

Adding CAC Score to Framingham Risk Scoring Re-Classified 1/4 of the 6814 Patients in MESA 298 patients (5%) were re-classified as high risk based on the CAC –Their CV event rate was 16% 744 patients (16%) were re-classified as low risk –Their CV event rate was 2%

Combination Therapy “Clinicians treating high risk patients who have a less than anticipated response to statins, who are unable to tolerate a less than recommended intensity of a statin or who are completely statin intolerant, may consider the addition of non-statin cholesterol lowering therapy”

Recommended LDL goal is <100 mg/dL – If a high-risk person has high triglycerides or low HDL, consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug Grundy, S. et al., Circulation 2004;110: High-Risk Persons Recommendations for Modifications to Footnote the ATP III Treatment Algorithm for LDL Levels

Niacin—AIM-HIGH ASCVD pts with low HDL, elevated triglycerides (150–400 mg/dL), and LDL 40–80 mg/dL compared simvastatin (+/- ezetimibe) plus niacin-SR 1,500–2,000 mg vs. simvastatin (+/- ezetimibe) plus placebo. Niacin lowered LDL levels an additional 6%, increased HDL by an additional 14%, reduced triglycerides by an additional 23%. Yet there was no change in rates of CV events in subgroups by age, sex, diabetes, metabolic syndrome or previous myocardial infarction status. There were similar rates of adverse events.

Ezetimibe—IMPROVE-IT RCT of high risk ACS patients comparing simvastatin 40 mg alone vs. simvastatin 40 mg + ezetimibe 10 mg Ezetimibe + simvastatin group showed a 17% reduction in LDL levels (53 vs 70 mg/dL) c/w simvastatin alone. After 7-year follow-up period, a “modest” benefit was seen: – 2% absolute reduction and 6% relative reduction in rates of CV death, MI, ACS, revascularization, and ischemic stroke (p<.05) –All-cause mortality was not affected.

Statin Safety Recommendations Check baseline ALT prior to initiating the statin Check LFTs if patient develops symptoms of hepatic dysfunction If 2 consecutive LDL <40, consider decreasing the statin dose (Grade C, weak recommendation) Simvastatin 80mg dose may be harmful Conditions that could predispose pts to statin side effects: o Impaired renal or hepatic function o History of previous statin intolerance or muscle disorder o Age >75 o Unexplained ALT elevation > 3x ULN o History of hemorrhagic stroke o Asian ancestry

Statin Drug Interactions(CYP3A4) Lovastatin/Simvastatin> Atorvastatin>Pravastatin/Rosuvastatin Amiodarone and dronedarone Antifungals (fluconazole, ketoconazole) Ca++ channel Blockers Colchicine Cyclosporine Erythromycin, clarithromycin, telithromycin Protease inhibitors Ranolazine Ticagrelor Grapefruit juice

Risk of Diabetes from Statins Very modest excess risk of new onset diabetes in RCTs and meta-analyses of RCTs (1 excess case per 1000 treated x 1 year with moderate-intensity statins; 3 excess cases per 1000 treated with high- intensity statins) Risk confined to those with risk factors for diabetes--also at higher risk of ASCVD Statin therapy still indicated

Risk of Memory Loss from Statins The panel found NO evidence that statins had an adverse effect on cognitive changes or risk of dementia. Despite initial promising results from observational studies, 2 RCTs in Alzheimer’s disease showed no benefit from statins in protecting against cognitive decline.

Rhabdomyolysis With the exception of simvastatin 80 mg, intensive- and moderate-dose statins did not increase the risk for rhabdomyolysis. In RCTs of statin therapy, rhabdomyolysis occurred rarely (<0.06% over a mean 5-year treatment period). In adults with CHD, the rate of CK>3 times ULN occurs at a similar rate in those treated with intensive- or moderate-dose statin therapy.

Myalgias In adults with and without CVD, statin-treated individuals in 14 clinical trials are not more likely to discontinue treatment than placebo-treated individuals. In adults with and without CVD in clinical trials, low- to moderate-dose statins do not increase the risk for myalgias or muscle pain. No evidence to support the use of Coenzyme Q10 Switching statins, alternate-day or once-weekly dosing regimens are best approach.

PCSK9 is a Key Regulator of LDLR Recycling PCSK9 mediates degradation of the LDLR by interacting with the extracellular domain and targeting the receptor for degradation 1 1. Horton JD, et al. J Lipid Res. 2009;50:S172-S Qian YW, et al. J Lipid Res. 2007;48: Zhang DW, et al. J Biol Chem. 2007;282: LDL = low-density lipoprotein; LDLR = low-density lipoprotein receptor LDLR/PCSK9 routed to lysosome Lysosomal degradation PCSK9 secretion Decreased LDLR surface concentration 24

PCSK9 Inhibition by Evolocumab or Alirocumab SQ administered monoclonal antibody given twice per month ($14,600/yr) 70% LDL-C reduction within weeks FDA approved this summer Safety profile encouraging Alternative to statin intolerant or resistant patients, particularly with FH No outcomes trial results

26